India's Bharat Biotech poised to enter clinic with Zika vaccine, report says

Research

Chasing two U.S.-developed vaccine candidates, India’s Bharat Biotech says it’s ready to start testing its Zika shot in humans. It just needs the go-ahead from Indian officials to get started, according to a local media report.

The company has wrapped up preclinical work on Zikavac, an inactivated shot that Bharat believes could win fast-track support from authorities, and is awaiting a government nod to proceed, according to Livemint. India is among the countries most vulnerable to a Zika outbreak, a recent Lancet study found.

Bharat’s proposed Phase I trial would test the vaccine in about 100 participants, Livemint reported.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Earlier this year, as the Zika outbreak exploded around the globe and companies started jumping into the R&D fray, Bharat Biotech was routinely named as a frontrunner. Now, if it’s able to advance its candidate, the biotech would be among the first organizations to enter the clinic.

Inovio Pharmaceuticals and the U.S. National Institutes of Health have entered Phase I with their Zika vaccine candidates. Inovio hit the milestone first, in June, and NIH followed up in August.

Analysts estimate a Zika vaccine could be a $1 billion opportunity, or more, because travelers from the U.S. and Europe would be able to pay a high price for protection. In endemic areas, disease experts envision vaccination campaigns targeting girls before puberty, because of the virus' links to birth defects. In boys, a vaccine could protect against future sexual transmission.

Larger companies in the Zika vaccine R&D effort are Sanofi, GlaxoSmithKline and Takeda, which each have paired with U.S. government entities to advance their research.

Related Articles:
Inovio kicks off its second Zika vax trial
Thanks to travelers, Zika could be a $1B+ vaccine opportunity: Reuters
Sanofi enlists for top Army hospital’s fight against Zika virus
Takeda joins frenzied Zika vaccine hunt in $312M deal with U.S. government
GSK jumps into Zika vax hunt on heels of Sanofi's deal
NIH kicks off PhI trial for Zika vax as caseload rises in U.S.

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.